Erratum: Smart adenovirus nanocomplexes for systemic delivery (Gene Therapy and Regulation (2010) 5 (81-99) DOI: 10.1142/S1568558610000227);Smart adenovirus nanocomplexes for systemic delivery

Gene Therapy and Regulation

Volumn 5, Issue 1, 2010, Pages 81-99

  Kang, Eunah ^a   Yun, Chae Ok ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adenovirus; adenovirus nanocomplex; chitosan; nanomaterial; oncolytic adenovirus; PEG; pHPMA; polymer

Indexed keywords

ADENOVIRUS VECTOR; CHITOSAN; LIPID; MACROGOL; NANOMATERIAL; NANOPARTICLE; POLY N (2 HYDROXYPROPYL)METHACRYLAMIDE; POLYMER; UNCLASSIFIED DRUG;

ADENOVIRUS; BLOODSTREAM INFECTION; CANCER GENE THERAPY; CANCER THERAPY; CHEMICAL ANALYSIS; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; METASTASIS; NONHUMAN; SURFACE PROPERTY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE;

EID: 78149461395     PISSN: 13889532     EISSN: 15685586     Source Type: Journal    
DOI: 10.1142/S1568558611000271     Document Type: Erratum

References (67)

1. Alemany, R., Balague, C. and Curiel, D. T. (2000). Replicative adenoviruses for cancer therapy. Nat Biotechnol, 18: 723-727.
2. Baker, A. H., McVey, J. H., Waddington, S. N., Di Paolo, N. C. and Shayakhmetov, D. M. (2007). The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther, 15: 1410-1416.
3. Barton, K. N., Stricker, H., Kolozsvary, A., Kohl, R., Heisey, G., Nagaraja, T. N., Zhu, G., Lu, M., Kim, J. H., Freytag, S. O. and Brown, S. L. (2006). Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy. J Urol, 175: 1921-1925.
4. Bonsted, A., Engesaeter, B. O., Hogset, A., Maelandsmo, G. M., Prasmickaite, L., D'Oliveira, C., Hennink, W. E., van Steenis, J. H. and Berg, K. (2006). Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J Gene Med, 8: 286-297.
5. Cattaneo, R., Miest, T., Shashkova, E. V. and Barry, M. A. (2008). Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol, 6: 529-540.
6. Chan, P., Kurisawa, M., Chung, J. E. and Yang, Y. Y. (2007). Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials, 28: 540-549.
7. Chen, L., Chen, D., Gong, M., Na, M., Li, L., Wu, H., Jiang, L., Qian, Y., Fang, G. and Xue, X. (2009). Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett, 284: 141-148.
8. Chengalvala, M. V., Lubeck, M. D., Selling, B. J., Natuk, R. J., Hsu, K. H., Mason, B. B., Chanda, P. K., Bhat, R. A., Bhat, B. M., Mizutani, S. and et al. (1991). Adenovirus vectors for gene expression. Curr Opin Biotechnol, 2: 718-722.
9. Choi, I. K., Lee, Y. S., Yoo, J. Y., Yoon, A. R., Kim, H., Kim, D. S., Seidler, D. G., Kim, J. H. and Yun, C. O. (2010). Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther, 17: 190-201.
10. Decuzzi, P., Pasqualini, R., Arap, W. and Ferrari, M. (2009). Intravascular delivery of particulate systems: does geometry really matter? Pharm Res, 26: 235-243.
11. Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E. and Barry, M. A. (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther, 20: 975-988.
12. Eto, Y., Gao, J. Q., Sekiguchi, F., Kurachi, S., Katayama, K., Maeda, M., Kawasaki, K., Mizuguchi, H., Hayakawa, T., Tsutsumi, Y., Mayumi, T. and Nakagawa, S. (2005). PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med, 7: 604-612.
13. Fisher, K. D. and Seymour, L. W. (2010). HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev, 62: 240-245.
14. Fisher, K. D., Stallwood, Y., Green, N. K., Ulbrich, K., Mautner, V. and Seymour, L. W. (2001). Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther, 8: 341-348.
15. Gao, J. Q., Eto, Y., Yoshioka, Y., Sekiguchi, F., Kurachi, S., Morishige, T., Yao, X. Watanabe, H., Asavatanabodee, R., Sakurai, F., Mizuguchi, H., Okada, Y., Mukai, Y., Tsutsumi, Y., Mayumi, T., Okada, N. and Nakagawa, S. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release, 122: 102-110.
16. Gomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C., Chen, S., Chang, D., Hernandez-Alcoceba, R., Newman, J. T., Stone, M. J. and Tong, A. W. (2009). Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res, 15: 1317-1325.
17. Green, N. K., Herbert, C. W., Hale, S. J., Hale, A. B., Mautner, V., Harkins, R., Hermiston, T., Ulbrich, K., Fisher, K. D. and Seymour, L. W. (2004). Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther, 11: 1256-1263.
18. Green, N. K., Morrison, J., Hale, S., Briggs, S. S., Stevenson, M., Subr, V., Ulbrich, K., Chandler, L., Mautner, V., Seymour, L. W. and Fisher, K. D. (2008). Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med, 10: 280-289.
19. Gressner, A. M. and Pfeiffer, T. (1986). Preventive effects of acute inflammation on liver cell necrosis and inhibition of heparan sulphate synthesis in hepatocytes. J Clin Chem Clin Biochem, 24: 821-829.
20. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson, Johannes, A.-, Williams, A., Hawkins, L. and Kirn, D. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med, 6: 1134-1139.
21. Hofherr, S. E., Mok, H., Gushiken, F. C., Lopez, J. A. and Barry, M. A. (2007). Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther, 18: 837-848.
22. Hofherr, S. E., Shashkova, E. V., Weaver, E. A., Khare, R. and Barry, M. A. (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther, 16: 1276-1282.
23. Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M., Nishimura, H. and Matsushima, A. (1995). Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol, 13: 86-91.
24. Jung, Y., Park, H. J., Kim, P. H., Lee, J., Hyung, W., Yang, J., Ko, H., Sohn, J. H. Kim, J. H., Huh, Y. M., Yun, C. O. and Haam, S. (2007). Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release, 123: 164-171.
25. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K. and Kirn, D. H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6: 879-885.
26. Kiang, A., Hartman, Z. C., Everett, R. S., Serra, D., Jiang, H., Frank,M. M. and Amalfitano, A. (2006). Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther, 14: 588-598.
27. Kim, J. H., Lee, Y. S., Kim, H., Huang, J. H., Yoon, A. R. and Yun, C. O. (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst, 98: 1482-1493.
28. Kim, P. H., Kim, T. I., Yockman, J. W., Kim, S. W. and Yun, C. O. (2010). The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials, 31: 1865-1874 [Epub 2009 Dec 3].
29. Kovacs, E. W., Hooker, J. M., Romanini, D.W., Holder, P. G., Berry, K. E. and Francis, M. B. (2007). Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjug Chem, 18: 1140-1147.
30. Kreppel, F. and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Mol Ther, 16: 16-29.
31. Lanciotti, J., Song, A., Doukas, J., Sosnowski, B., Pierce, G., Gregory, R., Wadsworth, S. and O'Riordan, C. (2003). Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther, 8: 99-107.
32. Lee, G. K., Maheshri, N., Kaspar, B. and Schaffer, D. V. (2005). PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng, 92: 24-34.
33. Lee, S., Ravindran, S. and Vellekamp, G. (2007). Investigations of PEGylated recombinant adenovirus, using fluorescein-labeled polyethylene glycol. Hum Gene Ther, 18: 286-300.
34. Li, F., Zhang, Z. P., Peng, J., Cui, Z. Q., Pang, D. W., Li, K., Wei, H. P., Zhou, Y. F., Wen, J. K. and Zhang, X. E. (2009). Imaging viral behavior in Mammalian cells with self-assembled capsid-quantum-dot hybrid particles. Small, 5: 718-726.
35. Li, K., Chen, Y., Li, S., Nguyen,H.G., Niu, Z., You, S.,Mello, C.M., Lu, X. andWang, Q. (2010). Chemical Modification of M13 Bacteriophage and Its Application in Cancer Cell Imaging. Bioconjug Chem, 21: 1369-1377.
36. Lyons, M., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazan-Peregrino, M., Phipps, S., Hale, S., Mautner, V., Seymour, L. W. and Fisher, K. D. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther, 14: 118-128.
37. Maeda, M., Kida, S., Hojo, K., Eto, Y., Gaob, J. Q., Kurachi, S., Sekiguchi, F., Mizuguchi, H., Hayakawa, T., Mayumi, T., Nakagawa, S. and Kawasaki, K. (2005). Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg Med Chem Lett, 15: 621-624.
38. Mok, H., Palmer, D. J., Ng, P. and Barry, M. A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther, 11: 66-79.
39. Mok, H., Park, J. W. and Park, T. G. (2008). Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjug Chem, 19: 797-801.
40. Morrison, J., Briggs, S. S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S. and Seymour, L. W. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther, 16: 244-251.
41. Morrison, J., Briggs, S. S., Green, N. K., Thoma, C., Fisher, K. D., Kehoe, S. and Seymour, L. W. (2009). Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther, 20: 239-251.
42. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD genedeleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res, 60: 6359-6366.
43. Niu, G., Xiong, Z., Cheng, Z., Cai, W., Gambhir, S. S., Xing, L. and Chen, X. (2007). In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol., 9: 126-134.
44. Ogawara, K., Rots, M. G., Kok, R. J., Moorlag, H. E., Van Loenen, A. M., Meijer, D. K., Haisma, H. J. and Molema, G. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther, 15: 433-443.
45. Oh, I. K., Mok, H. and Park, T. G. (2006). Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug Chem, 17: 721-727.
46. O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E. and Francis, G. E. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vitro. Hum Gene Ther, 10: 1349-1358.
47. Park, J. W., Mok, H. and Park, T. G. (2008). Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun, 366: 769-774.
48. Park, Y.,Kang, E.,Kwon, O. J.,Hwang,T., Park,H., Lee, J.M.,Kim, J.H. andYun,C.O. (2010). Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Control Release, 2010 Jul 15. [Epub ahead of print].
49. Parker, A. L., Waddington, S. N., Nicol, C. G., Shayakhmetov, D. M., Buckley, S. M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J. H., Nicklin, S. A. and Baker, A. H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108: 2554-2561.
50. Pearce, O. M., Fisher, K. D., Humphries, J., Seymour, L. W., Smith, A. and Davis, B. G. (2005). Glycoviruses: Chemical glycosylation retargets adenoviral gene transfer. Angew Chem Int Ed Engl, 44: 1057-1061.
51. Saini, V., Martyshkin, D. V., Mirov, S. B., Perez, A., Perkins, G., Ellisman, M. H. Towner, V. D., Wu, H., Pereboeva, L., Borovjagin, A., Curiel, D. T. and Everts, M. (2008). An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Small, 4: 262-269.
52. Sarkar, D., Lebedeva, I. V., Su, Z. Z., Park, E. S., Chatman, L., Vozhilla, N., Dent, P., Curiel, D. T. and Fisher, P. B. (2007). Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res, 67: 5434-5442.
53. Sarkar, D., Su, Z. Z. and Fisher, P. B. (2006). Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy. Cell Cycle, 5: 1531-1536.
54. Schneider, G. F., Subr, V., Ulbrich, K. and Decher, G. (2009). Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett, 9: 636-642.
55. Seiradake, E., Henaff, D., Wodrich, H., Billet, O., Perreau, M., Hippert, C., Mennechet, F., Schoehn, G., Lortat-Jacob, H., Dreja, H., Ibanes, S., Kalatzis, V.,Wang, P. J., Finberg, R. W., Cusack, S. and Kremer, E. J. (2009). The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog, 5(1): e1000277.
56. Shayakhmetov, D. M., Li, Z. Y., Ni, S. and Lieber, A. (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol, 78: 5368-5381.
57. Shibata, H., Yoshioka, Y., Ikemizu, S., Kobayashi, K., Yamamoto, Y., Mukai, Y., Okamoto, T. Taniai, M., Kawamura, M., Abe, Y., Nakagawa, S., Hayakawa, T., Nagata, S., Yamagata, Y., Mayumi, T., Kamada, H. and Tsutsumi, Y. (2004). Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res, 10: 8293-8300.
58. Singh, R., Al, Jamal, K. T.-, Lacerda, L. and Kostarelos, K. (2008). Nanoengineering artificial lipid envelopes around adenovirus by self-assembly. ACS Nano, 2: 1040-1050.
59. Singh, R. and Kostarelos, K. (2009). Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol, 27: 220-229.
60. Steinwaerder, D. S., Carlson, C. A., Otto, D. L., Li, Z. Y., Ni, S. and Lieber, A. (2001). Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med, 7: 240-243.
61. Thompson, D. H. (2008). Adenovirus in a synthetic membrane wrapper: An example of hybrid vigor? ACS Nano, 2: 821-826.
62. Tsutsumi, Y., Tsunoda, S., Kamada, H., Kihira, T., Nakagawa, S., Kaneda, Y., Kanamori, T. and Mayumi, T. (1996). Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. Br J Cancer, 74: 1090-1095.
63. Yao, X., Yoshioka, Y., Morishige, T., Eto, Y., Watanabe, H., Okada, Y., Mizuguchi, H., Mukai, Y., Okada, N. and Nakagawa, S. (2009). Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther, 16: 1395-1404.
64. Yoo, J. Y.,Kim, J. H.,Kim, J., Huang, J. H., Zhang, S. N., Kang, Y. A.,Kim, H. and Yun, C. O. (2008). Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: Effects on antiangiogenesis and tumor growth inhibition. Gene Ther, 15: 635-651.
65. Zhang, Y. A., Nemunaitis, J., Samuel, S. K., Chen, P., Shen, Y. and Tong, A. W. (2006). Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res, 66: 9736-9743.
66. Zhao, L., Dong, A., Gu, J., Liu, Z., Zhang, Y., Zhang,W.,Wang, Y., He, L., Qian, C., Qian, Q. and Liu, X. (2006). The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther, 13: 1011-1022.
67. Zhou,W., Yuan, X.,Wilson, A., Yang, L., Mokotoff, M., Pitt, B. and Li, S. (2002). Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem, 13: 1220-1225.